Ko JL - Search Results

1

Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines.

Chang JT, Chang GC, Ko JL, Liao HY, Liu HJ, Chen CC, Su JM, Lee H, Sheu GT. Chang JT, et al. Among authors: ko jl. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372. Int J Cancer. 2006. PMID: 16080190

2

MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.

Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. Ko JL, et al. Int J Cancer. 2000 May 20;89(3):265-70. doi: 10.1002/1097-0215(20000520)89:3<265::aid-ijc9>3.0.co;2-n. Int J Cancer. 2000. PMID: 10861503

3

A novel p53 mutant retained functional activity in lung carcinomas.

Ko JL, Chiao MC, Chang SL, Lin P, Lin JC, Sheu GT, Lee H. Ko JL, et al. DNA Repair (Amst). 2002 Sep 4;1(9):755-62. doi: 10.1016/s1568-7864(02)00094-0. DNA Repair (Amst). 2002. PMID: 12509279

4

Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas.

Wu TC, Lin P, Hsu CP, Huang YJ, Chen CY, Chung WC, Lee H, Ko JL. Wu TC, et al. Among authors: ko jl. Lung Cancer. 2003 Aug;41(2):163-9. doi: 10.1016/s0169-5002(03)00195-8. Lung Cancer. 2003. PMID: 12871779

5

Reduction of androgen receptor expression by benzo[alpha]pyrene and 7,8-dihydro-9,10-epoxy-7,8,9,10-tetrahydrobenzo[alpha]pyrene in human lung cells.

Lin P, Chang JT, Ko JL, Liao SH, Lo WS. Lin P, et al. Among authors: ko jl. Biochem Pharmacol. 2004 Apr 15;67(8):1523-30. doi: 10.1016/j.bcp.2003.12.018. Biochem Pharmacol. 2004. PMID: 15041469

6

Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines.

Weng MW, Lai JC, Hsu CP, Yu KY, Chen CY, Lin TS, Lai WW, Lee H, Ko JL. Weng MW, et al. Among authors: ko jl. Environ Mol Mutagen. 2005 Jul;46(1):1-11. doi: 10.1002/em.20118. Environ Mol Mutagen. 2005. PMID: 15714438

7

Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.

Hsu CP, Shen GH, Ko JL. Hsu CP, et al. Among authors: ko jl. Lung Cancer. 2006 Jun;52(3):349-57. doi: 10.1016/j.lungcan.2006.01.011. Epub 2006 Mar 29. Lung Cancer. 2006. PMID: 16569461 Clinical Trial.

8

Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter--effect on telomerase expression and telomere length maintenance in non-small cell lung cancer.

Hsu CP, Hsu NY, Lee LW, Ko JL. Hsu CP, et al. Among authors: ko jl. Eur J Cancer. 2006 Jul;42(10):1466-74. doi: 10.1016/j.ejca.2006.02.014. Epub 2006 Jun 5. Eur J Cancer. 2006. PMID: 16737810

9

Modulation of telomere shelterin by TRF1 [corrected] and TRF2 interacts with telomerase to maintain the telomere length in non-small cell lung cancer.

Hsu CP, Ko JL, Shai SE, Lee LW. Hsu CP, et al. Among authors: ko jl. Lung Cancer. 2007 Dec;58(3):310-6. doi: 10.1016/j.lungcan.2007.06.019. Epub 2007 Aug 2. Lung Cancer. 2007. PMID: 17681636

10

Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae.

Liao CH, Hsiao YM, Sheu GT, Chang JT, Wang PH, Wu MF, Shieh GJ, Hsu CP, Ko JL. Liao CH, et al. Among authors: ko jl. Biochem Pharmacol. 2007 Nov 15;74(10):1541-54. doi: 10.1016/j.bcp.2007.07.025. Epub 2007 Jul 22. Biochem Pharmacol. 2007. PMID: 17720143

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters